Compass Therapeutics Past Earnings Performance
Past criteria checks 0/6
Compass Therapeutics's earnings have been declining at an average annual rate of -4.2%, while the Biotechs industry saw earnings growing at 19.7% annually. Revenues have been growing at an average rate of 171.4% per year.
Key information
-4.2%
Earnings growth rate
52.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 171.4% |
| Return on equity | -32.3% |
| Net Margin | -5,557.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth
Jun 05
We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely
Feb 13Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth
Sep 20Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial
Oct 11Revenue & Expenses Breakdown
How Compass Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -47 | 14 | 42 |
| 31 Mar 24 | 0 | -45 | 12 | 41 |
| 31 Dec 23 | 0 | -42 | 12 | 38 |
| 30 Sep 23 | 0 | -41 | 12 | 36 |
| 30 Jun 23 | 0 | -43 | 12 | 37 |
| 31 Mar 23 | 0 | -40 | 12 | 32 |
| 31 Dec 22 | 0 | -39 | 12 | 30 |
| 30 Sep 22 | 0 | -41 | 12 | 30 |
| 30 Jun 22 | 0 | -35 | 12 | 23 |
| 31 Mar 22 | 0 | -82 | 11 | 20 |
| 31 Dec 21 | 0 | -82 | 11 | 20 |
| 30 Sep 21 | 0 | -78 | 11 | 15 |
| 30 Jun 21 | 0 | -81 | 13 | 16 |
| 31 Mar 21 | 0 | -31 | 13 | 16 |
| 31 Dec 20 | 0 | -29 | 13 | 15 |
| 30 Sep 20 | 0 | -28 | 12 | 14 |
| 30 Jun 20 | 0 | -27 | 9 | 16 |
| 31 Mar 20 | 0 | -30 | 11 | 19 |
| 31 Dec 19 | 0 | -35 | 12 | 22 |
Quality Earnings: CMPX is currently unprofitable.
Growing Profit Margin: CMPX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CMPX is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.
Accelerating Growth: Unable to compare CMPX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CMPX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: CMPX has a negative Return on Equity (-32.33%), as it is currently unprofitable.